Sinopharm Group
Market Cap
HK$81.7b
Last Updated
2020/02/23 12:54 UTC
Data Sources
Company Financials +
Executive Summary
Sinopharm Group Co., Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products in the People’s Republic of China.
Rewards
Risk Analysis
Snowflake Analysis
Established dividend payer and good value.
Similar Companies
Share Price & News
How has Sinopharm Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1099 has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
1.6%
1099
-0.1%
HK Healthcare
-0.6%
HK Market
1 Year Return
-22.0%
1099
-22.8%
HK Healthcare
-7.6%
HK Market
Return vs Industry: 1099 matched the Hong Kong Healthcare industry which returned -22.8% over the past year.
Return vs Market: 1099 underperformed the Hong Kong Market which returned -7.6% over the past year.
Shareholder returns
| 1099 | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.6% | -0.1% | -0.6% |
| 30 Day | -5.2% | -4.1% | -1.2% |
| 90 Day | 0.6% | -5.7% | 3.0% |
| 1 Year | -20.1%-22.0% | -21.0%-22.8% | -4.2%-7.6% |
| 3 Year | -22.7%-27.4% | -30.2%-34.3% | 12.9%1.5% |
| 5 Year | 5.3%-3.5% | -22.9%-29.3% | 13.1%-5.6% |
Price Volatility Vs. Market
How volatile is Sinopharm Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall St
How Does Sinopharm Group Co., Ltd. (HKG:1099) Fare As A Dividend Stock?2 weeks ago | Simply Wall St
How Many Sinopharm Group Co., Ltd. (HKG:1099) Shares Do Institutions Own?3 weeks ago | Simply Wall St
Some Sinopharm Group (HKG:1099) Shareholders Are Down 22%Valuation
Is Sinopharm Group undervalued compared to its fair value and its price relative to the market?
34.4%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 1099 (HK$26.2) is trading below our estimate of fair value (HK$39.96)
Significantly Below Fair Value: 1099 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 1099 is good value based on its PE Ratio (11.7x) compared to the Healthcare industry average (16.3x).
PE vs Market: 1099 is poor value based on its PE Ratio (11.7x) compared to the Hong Kong market (10.1x).
Price to Earnings Growth Ratio
PEG Ratio: 1099 is good value based on its PEG Ratio (0.9x)
Price to Book Ratio
PB vs Industry: 1099 is overvalued based on its PB Ratio (1.5x) compared to the HK Healthcare industry average (1.5x).
Next Steps
Future Growth
How is Sinopharm Group forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
13.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1099's forecast earnings growth (13.5% per year) is above the savings rate (1.6%).
Earnings vs Market: 1099's earnings (13.5% per year) are forecast to grow faster than the Hong Kong market (11.8% per year).
High Growth Earnings: 1099's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1099's revenue (10.4% per year) is forecast to grow faster than the Hong Kong market (9.6% per year).
High Growth Revenue: 1099's revenue (10.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1099's Return on Equity is forecast to be low in 3 years time (14.6%).
Next Steps
Past Performance
How has Sinopharm Group performed over the past 5 years?
15.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1099 has high quality earnings.
Growing Profit Margin: 1099's current net profit margins (1.6%) are lower than last year (1.6%).
Past Earnings Growth Analysis
Earnings Trend: 1099's earnings have grown by 15.3% per year over the past 5 years.
Accelerating Growth: 1099's earnings growth over the past year (14.3%) is below its 5-year average (15.3% per year).
Earnings vs Industry: 1099 earnings growth over the past year (14.3%) exceeded the Healthcare industry 10.4%.
Return on Equity
High ROE: 1099's Return on Equity (14.1%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Sinopharm Group's financial position?
Financial Position Analysis
Short Term Liabilities: 1099's short term assets (CN¥248.9B) exceed its short term liabilities (CN¥198.3B).
Long Term Liabilities: 1099's short term assets (CN¥248.9B) exceed its long term liabilities (CN¥14.8B).
Debt to Equity History and Analysis
Debt Level: 1099's debt to equity ratio (63.3%) is considered high.
Reducing Debt: 1099's debt to equity ratio has reduced from 81.2% to 63.3% over the past 5 years.
Debt Coverage: 1099's debt is not well covered by operating cash flow (4.5%).
Interest Coverage: 1099's interest payments on its debt are well covered by EBIT (4.2x coverage).
Balance Sheet
Inventory Level: 1099 has a high level of physical assets or inventory.
Debt Coverage by Assets: 1099's debt is covered by short term assets (assets are 5.3x debt).
Next Steps
Dividend
What is Sinopharm Group's current dividend yield, its reliability and sustainability?
2.50%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: 1099's dividend (2.5%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.29%).
High Dividend: 1099's dividend (2.5%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.34%).
Stability and Growth of Payments
Stable Dividend: 1099's dividends per share have been stable in the past 10 years.
Growing Dividend: 1099's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (29.2%), 1099's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 1099's dividends in 3 years are forecast to be well covered by earnings (29% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
8.5yrs
Average management tenure
CEO
Yong Liu (50yo)
2.3yrs
Tenure
CN¥7,918,000
Compensation
Mr. Yong Liu serves as the Chief Legal Advisor at Sinopharm Group Co. Ltd. and served as its Joint Company Secretary since October 28, 2016 until August 24, 2018. Mr. Liu is Executive Director of Sinopharm ...
CEO Compensation Analysis
Compensation vs Market: Yong's total compensation ($USD1.13M) is about average for companies of similar size in the Hong Kong market ($USD1.05M).
Compensation vs Earnings: Yong's compensation has increased by more than 20% in the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 2.9yrs | CN¥10.94m | 0.0056% CN¥4.6m | |
| President & Executive Director | 2.3yrs | CN¥7.92m | 0.0045% CN¥3.7m | |
| Executive Director | 1.7yrs | CN¥15.89m | 0.0032% CN¥2.6m | |
| Company Secretary | 1.2yrs | no data | no data | |
| Vice President | 0yrs | no data | no data | |
| Vice President | 2.1yrs | no data | no data | |
| CFO & Vice President | 9.8yrs | no data | no data | |
| Joint Company Secretary | 8.5yrs | no data | no data | |
| Non-Executive Vice President | 8.9yrs | no data | no data | |
| Vice President | 9.4yrs | no data | no data |
8.5yrs
Average Tenure
51.5yo
Average Age
Experienced Management: 1099's management team is seasoned and experienced (8.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 2.9yrs | CN¥10.94m | 0.0056% CN¥4.6m | |
| President & Executive Director | 2.3yrs | CN¥7.92m | 0.0045% CN¥3.7m | |
| Executive Director | 1.7yrs | CN¥15.89m | 0.0032% CN¥2.6m | |
| Chairman of Supervisory Committee | 9.1yrs | no data | no data | |
| Non-Executive Director | 3.3yrs | no data | no data | |
| Vice Chairman | 6.3yrs | no data | no data | |
| Independent Non Executive Director | 3.9yrs | CN¥300.00k | no data | |
| Non-Executive Director | 12.5yrs | no data | no data | |
| Independent Non-Executive Director | 5.4yrs | CN¥300.00k | no data | |
| Independent Non-Executive Director | 5.4yrs | CN¥300.00k | no data |
4.7yrs
Average Tenure
55.5yo
Average Age
Experienced Board: 1099's board of directors are considered experienced (4.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 1099 insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.9%.
Top Shareholders
Company Information
Sinopharm Group Co., Ltd.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Sinopharm Group Co., Ltd.
- Ticker: 1099
- Exchange: SEHK
- Founded: 2003
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: HK$81.656b
- Shares outstanding: 3.12b
- Website: https://www.sinopharmgroup.com.cn
Number of Employees
Location
- Sinopharm Group Co., Ltd.
- Sinopharm Plaza
- No. 1001 Zhongshan Road (West)
- Shanghai
- 200051
- China
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 1099 | SEHK (The Stock Exchange of Hong Kong Ltd.) | Yes | Foreign Shares-Foreign Listed | HK | HKD | Sep 2009 |
| SHTD.F | OTCPK (Pink Sheets LLC) | Yes | Foreign Shares-Foreign Listed | US | USD | Sep 2009 |
| X2S | DB (Deutsche Boerse AG) | Yes | Foreign Shares-Foreign Listed | DE | EUR | Sep 2009 |
| 1099 | SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect) | Yes | Foreign Shares-Foreign Listed | HK | HKD | Sep 2009 |
| 1099 | SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect) | Yes | Foreign Shares-Foreign Listed | HK | HKD | Sep 2009 |
| SHTD.Y | OTCPK (Pink Sheets LLC) | ADR | US | USD | Aug 2012 |
Biography
Sinopharm Group Co., Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products in the People’s Republic of China. Its Pharmaceutical Distribution segment offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. This segment distributes medicines, medical devices, and pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. The company’s Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2018, this segment had 5,183 retail pharmacies. Its Medical Devices segment distributes medical devices. Its Other Business segment engages in the production, sale, and financial leasing of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. The company was founded in 2003 and is headquartered in Shanghai, the People’s Republic of China.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/23 12:54 |
| End of Day Share Price | 2020/02/21 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.